Video yükleniyor...

Video Yüklenemedi

Ana Sayfaya Dön

🚀 How Recursion used AI to identify a novel approach for potentially treating the rare disease Familial Adenomatous Polyposis (FAP). A new video shares the story of Recursion’s investigational drug REC-4881 for the rare disease FAP which affects more than 50,000 people in the US and EU5 and has...

RecursionPharma's profile picture

Recursion

17,305 subscribers

11,944 görüntüleme • 6 ay önce •via X (Twitter)

LIVE

Anya Rossi• Live Now

Private livecam show

0 Yorum

Yorum bulunmuyor

Orijinal gönderinin yorumları burada görünecek

Benzer Videolar

🔹 AI drug discovery, validated. Recursion recently announced the first clinical validation of its AI-enabled drug discovery platform – positive Phase 1b/2 data for the ongoing TUPELO study evaluating its AI-identified drug, REC-4881, in Familial Adenomatous Polyposis (FAP). This progressive rare disease affects more than 50,000 people in the U.S. and EU and has no FDA-approved treatments. It results in hundreds to thousands of polyps developing in the colon, and requires a lifetime of invasive surveillance and surgery. Recursion used AI not only to deliver the first potential treatment for this disease but also to quantify – for the first time at scale – the true natural progression of polyp burden in the trial-relevant population. It demonstrates the incredible breakthroughs that can come from merging proprietary data and AI – and the tangible impact on patient lives. 👉 See the full study results here:
1:29

🔹 AI drug discovery, validated. Recursion recently announced the first clinical validation of its AI-enabled drug discovery platform – positive Phase 1b/2 data for the ongoing TUPELO study evaluating its AI-identified drug, REC-4881, in Familial Adenomatous Polyposis (FAP). This progressive rare disease affects more than 50,000 people in the U.S. and EU and has no FDA-approved treatments. It results in hundreds to thousands of polyps developing in the colon, and requires a lifetime of invasive surveillance and surgery. Recursion used AI not only to deliver the first potential treatment for this disease but also to quantify – for the first time at scale – the true natural progression of polyp burden in the trial-relevant population. It demonstrates the incredible breakthroughs that can come from merging proprietary data and AI – and the tangible impact on patient lives. 👉 See the full study results here:

Recursion

255,879 görüntüleme • 8 ay önce

🚀 Reshaping drug discovery – and the future of medicine – with AI. Recursion CFO Ben Taylor joined the Opto Sessions podcast from CMC Aureon to share how Recursion uses AI, lab automation, biological data, and machine learning to improve the way new medicines are discovered and developed. 💠 They discuss: ▪️How pairing AI with lab automation across biology, chemistry, and clinical technology allows us to move beyond the ~10–12% of the genome currently addressed by approved or in-trial medicines and explore the vast realm of untapped biology. ▪️How Recursion is advancing REC-4881 for patients with familial adenomatous polyposis (FAP) — a progressive condition with no approved medical therapies — after achieving Phase 2 proof-of-concept and demonstrating meaningful reductions in polyp burden. ▪️How Recursion is compressing timelines and improving efficiency with high-quality, ML-ready data to design better molecules with ~90% fewer experimental chemistries and to run smarter, faster clinical trials. 👉 Check out the full conversation:
0:58

🚀 Reshaping drug discovery – and the future of medicine – with AI. Recursion CFO Ben Taylor joined the Opto Sessions podcast from CMC Aureon to share how Recursion uses AI, lab automation, biological data, and machine learning to improve the way new medicines are discovered and developed. 💠 They discuss: ▪️How pairing AI with lab automation across biology, chemistry, and clinical technology allows us to move beyond the ~10–12% of the genome currently addressed by approved or in-trial medicines and explore the vast realm of untapped biology. ▪️How Recursion is advancing REC-4881 for patients with familial adenomatous polyposis (FAP) — a progressive condition with no approved medical therapies — after achieving Phase 2 proof-of-concept and demonstrating meaningful reductions in polyp burden. ▪️How Recursion is compressing timelines and improving efficiency with high-quality, ML-ready data to design better molecules with ~90% fewer experimental chemistries and to run smarter, faster clinical trials. 👉 Check out the full conversation:

Recursion

87,246 görüntüleme • 1 ay önce

Today, Recursion reported our 4Q/FY25 business updates and financial results. As CEO and President Najat Khan said, “Recursion has reached an inflection point: moving from proving that AI can participate in drug discovery to demonstrating that an AI-native operating system can generate clinical proof and durable value.” This includes: 🚀 A 5th milestone with Sanofi for a first-in-class Sanofi-partnered oncology program against a historically difficult and novel biological space. This brings the total upfront and progress-based milestones to $134 million to date. Five Recursion discovery program packages have been accepted to date, establishing a growing joint portfolio of novel AI-driven small molecules for immunology and oncology. 🚀 The first AI-enabled clinical validation of the Recursion OS platform in our FAP program, demonstrating translation from AI-driven biological insight to meaningful patient outcomes. We also have multiple clinical and preclinical programs advancing with defined milestones. 🚀 New preclinical efficacy data for REC-7735, a potential best-in-class PI3K⍺ H1047R inhibitor, precision designed with 242 compounds synthesized from first novel hit to REC-7735 in 10 months using the Recursion OS platform. REC-7735 demonstrates >100-fold selectivity for the H1074R mutation over WT PI3K⍺ suggesting potential improved tolerability over current inhibitors and is currently in IND-enabling studies. 🚀 $754 million of cash and cash equivalents. We exceeded our original cost savings guidance and now expect runway into early 2028, without additional financing. 👉 Read the full business updates here: 🔹 Tune in to our Earnings Call today, February 25, 2026 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT, here on X, or on: ▪️ YouTube: ▪️ LinkedIn:
0:24

Today, Recursion reported our 4Q/FY25 business updates and financial results. As CEO and President Najat Khan said, “Recursion has reached an inflection point: moving from proving that AI can participate in drug discovery to demonstrating that an AI-native operating system can generate clinical proof and durable value.” This includes: 🚀 A 5th milestone with Sanofi for a first-in-class Sanofi-partnered oncology program against a historically difficult and novel biological space. This brings the total upfront and progress-based milestones to $134 million to date. Five Recursion discovery program packages have been accepted to date, establishing a growing joint portfolio of novel AI-driven small molecules for immunology and oncology. 🚀 The first AI-enabled clinical validation of the Recursion OS platform in our FAP program, demonstrating translation from AI-driven biological insight to meaningful patient outcomes. We also have multiple clinical and preclinical programs advancing with defined milestones. 🚀 New preclinical efficacy data for REC-7735, a potential best-in-class PI3K⍺ H1047R inhibitor, precision designed with 242 compounds synthesized from first novel hit to REC-7735 in 10 months using the Recursion OS platform. REC-7735 demonstrates >100-fold selectivity for the H1074R mutation over WT PI3K⍺ suggesting potential improved tolerability over current inhibitors and is currently in IND-enabling studies. 🚀 $754 million of cash and cash equivalents. We exceeded our original cost savings guidance and now expect runway into early 2028, without additional financing. 👉 Read the full business updates here: 🔹 Tune in to our Earnings Call today, February 25, 2026 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT, here on X, or on: ▪️ YouTube: ▪️ LinkedIn:

Recursion

11,878 görüntüleme • 5 ay önce

After relapsing on the only drug in development for my rare disease, my doctors told me ‘We’ve tried everything, there’s nothing more that we can do.’ To make things worse, I didn’t have a billion dollars and 10 years to develop a new drug from scratch. My only hope was to find a drug that was already FDA-approved that I could repurpose for my disease. It’s been over 9.5 years that I’ve been in remission and we have been able to identify and advance numerous treatments for diseases they weren’t initially intended for. Now through Every Cure we are utilizing artificial intelligence to maximize the potential of all existing drugs to treat every disease they possibly can. What rare disease would you like to find a repurposed drug to treat? #MedTwitter
0:53

After relapsing on the only drug in development for my rare disease, my doctors told me ‘We’ve tried everything, there’s nothing more that we can do.’ To make things worse, I didn’t have a billion dollars and 10 years to develop a new drug from scratch. My only hope was to find a drug that was already FDA-approved that I could repurpose for my disease. It’s been over 9.5 years that I’ve been in remission and we have been able to identify and advance numerous treatments for diseases they weren’t initially intended for. Now through Every Cure we are utilizing artificial intelligence to maximize the potential of all existing drugs to treat every disease they possibly can. What rare disease would you like to find a repurposed drug to treat? #MedTwitter

David Fajgenbaum, MD

138,669 görüntüleme • 2 yıl önce

ER100 is a new drug and potential gene therapy currently in its first clinical trial with 12 participants. The mechanism is not symptom management and not disease treatment. It targets the biological switch at the cellular level, instructing cells to revert to a different functional state. Conventional medicine has been built around treating disease after it occurs. This approach aims to reverse the biological aging process that underlies disease development. The trial is early and the sample size is small, but if the mechanism holds, the implications for human health and longevity are unlike anything medicine has produced. This conversation is worth following closely.
0:27

ER100 is a new drug and potential gene therapy currently in its first clinical trial with 12 participants. The mechanism is not symptom management and not disease treatment. It targets the biological switch at the cellular level, instructing cells to revert to a different functional state. Conventional medicine has been built around treating disease after it occurs. This approach aims to reverse the biological aging process that underlies disease development. The trial is early and the sample size is small, but if the mechanism holds, the implications for human health and longevity are unlike anything medicine has produced. This conversation is worth following closely.

Dr. Gabrielle Lyon

13,681 görüntüleme • 1 ay önce

We are thrilled to share positive topline data from our ELEVATE IPF Phase 2b trial evaluating deupirfenidone (LYT-100) for the treatment of idiopathic pulmonary fibrosis (#IPF), a progressive and fatal lung disease. Our trial met the primary and key secondary endpoints, with deupirfenidone demonstrating the potential to serve as a new standard of care. Over 26 weeks, the highest dose of deupirfenidone studied was generally well-tolerated and reduced lung function decline to levels that approach natural lung function decline in healthy adults over sixty—a first for any investigational or approved treatment for IPF. We’re incredibly excited for what deupirfenidone could offer the IPF community, which urgently needs new treatment options with better efficacy that don’t compromise on tolerability. A heartfelt thank you to everyone who participated in the ELEVATE IPF trial, including patients, caregivers, clinical trial sites, and advocacy groups. Your courage, dedication and expertise make progress possible, and we are grateful for your trust and partnership. Read more in today’s press release:
0:59

We are thrilled to share positive topline data from our ELEVATE IPF Phase 2b trial evaluating deupirfenidone (LYT-100) for the treatment of idiopathic pulmonary fibrosis (#IPF), a progressive and fatal lung disease. Our trial met the primary and key secondary endpoints, with deupirfenidone demonstrating the potential to serve as a new standard of care. Over 26 weeks, the highest dose of deupirfenidone studied was generally well-tolerated and reduced lung function decline to levels that approach natural lung function decline in healthy adults over sixty—a first for any investigational or approved treatment for IPF. We’re incredibly excited for what deupirfenidone could offer the IPF community, which urgently needs new treatment options with better efficacy that don’t compromise on tolerability. A heartfelt thank you to everyone who participated in the ELEVATE IPF trial, including patients, caregivers, clinical trial sites, and advocacy groups. Your courage, dedication and expertise make progress possible, and we are grateful for your trust and partnership. Read more in today’s press release:

PureTech

10,892 görüntüleme • 1 yıl önce

We’re excited to announce positive results from our BroADen Phase 1b clinical trial of KT-621, our investigational, first-in-class, oral STAT6 degrader, in patients with moderate to severe atopic dermatitis. The data provide a powerful validation of our industry-leading STAT6 degrader program and help accelerate our goal to deliver novel oral medicines to millions of patients around the world. Our deepest thanks to the patients, investigators, and the incredible Kymera team whose dedication made this significant milestone possible. Read more about the promising KT-621 data in our press release and join our live video webcast at 8:00AM ET today: #RevolutionizingImmunology
2:02

We’re excited to announce positive results from our BroADen Phase 1b clinical trial of KT-621, our investigational, first-in-class, oral STAT6 degrader, in patients with moderate to severe atopic dermatitis. The data provide a powerful validation of our industry-leading STAT6 degrader program and help accelerate our goal to deliver novel oral medicines to millions of patients around the world. Our deepest thanks to the patients, investigators, and the incredible Kymera team whose dedication made this significant milestone possible. Read more about the promising KT-621 data in our press release and join our live video webcast at 8:00AM ET today: #RevolutionizingImmunology

Kymera Therapeutics

15,395 görüntüleme • 8 ay önce

A few days ago, we learned that the first patient in the U.S., to our knowledge, has been dosed with lidocaine for their breast cancer treatment. Just six weeks ago, we learned about the potential connection between lidocaine and improved breast cancer outcomes from a groundbreaking clinical trial of 1,600 patients conducted in India. That study showed a potential 30% reduction in five-year mortality for patients who received lidocaine injections into their tumors before surgery. Since then, we've engaged in discussions with specialists and researchers, and what we’ve discovered has been surprising —no one seemed to be using this approach, despite the data available. The other day, one of those conversations turned into action. A doctor we spoke to decided to inject a tumor with lidocaine before removing it, marking a critical first step toward translating global insights into real-world patient care. This moment excites us because it shows the power of accelerating drug repurposing insights into clinical practice. At Every Cure, this is exactly what drives us: identifying overlooked opportunities and ensuring they reach patients who need them most—quickly and efficiently. #medtwitter
0:49

A few days ago, we learned that the first patient in the U.S., to our knowledge, has been dosed with lidocaine for their breast cancer treatment. Just six weeks ago, we learned about the potential connection between lidocaine and improved breast cancer outcomes from a groundbreaking clinical trial of 1,600 patients conducted in India. That study showed a potential 30% reduction in five-year mortality for patients who received lidocaine injections into their tumors before surgery. Since then, we've engaged in discussions with specialists and researchers, and what we’ve discovered has been surprising —no one seemed to be using this approach, despite the data available. The other day, one of those conversations turned into action. A doctor we spoke to decided to inject a tumor with lidocaine before removing it, marking a critical first step toward translating global insights into real-world patient care. This moment excites us because it shows the power of accelerating drug repurposing insights into clinical practice. At Every Cure, this is exactly what drives us: identifying overlooked opportunities and ensuring they reach patients who need them most—quickly and efficiently. #medtwitter

David Fajgenbaum, MD

55,765 görüntüleme • 1 yıl önce

Hello, my dear friends, we have some breaking news today! Our rentosertib (novel target that has never been in clinical trials before we picked it using AI, novel molecule designed using true generative AI with the published broadly used AI platform, targeting fibrosis and biology of aging) entered Phase III trial in Idiopathic Pulmonary Fibrosis. This is a major milestone in the life of every drug hunter - the ultimate test. To my knowledge, in our AI drug discovery industry, no other company took the drug for a novel target with a novel molecule into Phase III before so it is a big milestone for the entire industry. Of course, at Insilico we are no longer dependent on this program - we have 13 INDs and many clinical trials are ongoing internally and run by partners. But this program is very special as we also demonstrated the senomorphic properties of this drug and built the entire pipeline of molecules around this target. Please Wish Me Luck! Luck is the most important superpower in everything we do and if we succeed with this program and also demonstrate the antiaging effect - all of us will benefit. Godspeed, my friends and thanks to everyone who helped us along the way!
2:26

Hello, my dear friends, we have some breaking news today! Our rentosertib (novel target that has never been in clinical trials before we picked it using AI, novel molecule designed using true generative AI with the published broadly used AI platform, targeting fibrosis and biology of aging) entered Phase III trial in Idiopathic Pulmonary Fibrosis. This is a major milestone in the life of every drug hunter - the ultimate test. To my knowledge, in our AI drug discovery industry, no other company took the drug for a novel target with a novel molecule into Phase III before so it is a big milestone for the entire industry. Of course, at Insilico we are no longer dependent on this program - we have 13 INDs and many clinical trials are ongoing internally and run by partners. But this program is very special as we also demonstrated the senomorphic properties of this drug and built the entire pipeline of molecules around this target. Please Wish Me Luck! Luck is the most important superpower in everything we do and if we succeed with this program and also demonstrate the antiaging effect - all of us will benefit. Godspeed, my friends and thanks to everyone who helped us along the way!

Alex Zhavoronkov, PhD (aka Aleksandrs Zavoronkovs)

49,544 görüntüleme • 1 ay önce

Hey, I'm Dryka Brenda, and I'm facing a difficult battle against a rare genetic disease called Familial Adenomatous Polyposis (FAP). It's caused by a mutation in the APC gene, which my father and I both have, and it causes the growth of many polyps throughout the digestive system. FAP doesn't just affect the large intestine; it can also affect the stomach, duodenum, small intestine, and even other organs like the thyroid, liver, pancreas, adrenal glands, bones, and skin. It's a silent disease that spreads internally and, if left untreated, almost inevitably leads to cancer. We only discovered this mutation in 2023 when my father was diagnosed with two tumors in his intestine, one in the rectum and the other in the colon (synchronous tumors). After that, he and I underwent surgeries to remove our large intestines, but unfortunately, this disease is progressive and is now affecting our stomach and duodenum. This mutation has already caused a lot of pain in our family. My grandmother passed away from stomach cancer, my brother from leukemia, and now my father and I are in this fight. But there is hope: an experimental treatment and specialized follow-up at the Mayo Clinic in the United States (a world reference in rare and genetic diseases). Both my father and I will be treated there, and my mother will go along as our caregiver. We have already created a crowdfunding campaign to raise the necessary funds, but it is not enough, and we need to raise this amount by January 22nd, otherwise we will not be able to undergo the treatment. The Token fees will help me pay all the costs: passports, visas, tickets, food, accommodation, medical translations and unexpected costs that arise, and mainly, the treatment It's difficult to ask for help, but we are clinging to the chance to live with quality of life and the chance to control this disease. PAF requires continuous monitoring, and this could be a turning point in our treatment. Any amount is already a seed of hope. And if you can't donate or buy my token, sharing already helps a lot <3
1:30

Hey, I'm Dryka Brenda, and I'm facing a difficult battle against a rare genetic disease called Familial Adenomatous Polyposis (FAP). It's caused by a mutation in the APC gene, which my father and I both have, and it causes the growth of many polyps throughout the digestive system. FAP doesn't just affect the large intestine; it can also affect the stomach, duodenum, small intestine, and even other organs like the thyroid, liver, pancreas, adrenal glands, bones, and skin. It's a silent disease that spreads internally and, if left untreated, almost inevitably leads to cancer. We only discovered this mutation in 2023 when my father was diagnosed with two tumors in his intestine, one in the rectum and the other in the colon (synchronous tumors). After that, he and I underwent surgeries to remove our large intestines, but unfortunately, this disease is progressive and is now affecting our stomach and duodenum. This mutation has already caused a lot of pain in our family. My grandmother passed away from stomach cancer, my brother from leukemia, and now my father and I are in this fight. But there is hope: an experimental treatment and specialized follow-up at the Mayo Clinic in the United States (a world reference in rare and genetic diseases). Both my father and I will be treated there, and my mother will go along as our caregiver. We have already created a crowdfunding campaign to raise the necessary funds, but it is not enough, and we need to raise this amount by January 22nd, otherwise we will not be able to undergo the treatment. The Token fees will help me pay all the costs: passports, visas, tickets, food, accommodation, medical translations and unexpected costs that arise, and mainly, the treatment It's difficult to ask for help, but we are clinging to the chance to live with quality of life and the chance to control this disease. PAF requires continuous monitoring, and this could be a turning point in our treatment. Any amount is already a seed of hope. And if you can't donate or buy my token, sharing already helps a lot <3

dry

74,142 görüntüleme • 7 ay önce

Many have said that the differences and divisions in our world are too great for us to come together for the common good. But the Summit of the Future showed that with a spirit of dialogue and compromise, we can join forces to steer our world to a more sustainable path. As this year’s #UNGA activities wind down, we must remember that this is not the end. It is in all our interests to choose the future we want and to guide our world towards it. The journey continues. Let’s keep going.
0:42

Many have said that the differences and divisions in our world are too great for us to come together for the common good. But the Summit of the Future showed that with a spirit of dialogue and compromise, we can join forces to steer our world to a more sustainable path. As this year’s #UNGA activities wind down, we must remember that this is not the end. It is in all our interests to choose the future we want and to guide our world towards it. The journey continues. Let’s keep going.

António Guterres

110,801 görüntüleme • 1 yıl önce

Today, we announce our Q1 2026 business updates and financial results – demonstrating continued momentum across our internal portfolio and partnered programs, with multiple value-driving milestones on track. 🚀 Key proof points include: ▪️ REC-1245 (RBM39 degrader): Early clinical data demonstrate a well-tolerated safety profile and predictable, dose-dependent PK (n=16); dose escalation ongoing with no dose-limiting toxicities observed to date. ▪️ REC-4539 (LSD1 inhibitor): First patient dosed in Phase 1; platform-derived, selective, brain-penetrant profile with a reversible mechanism and shorter predicted half-life aimed at reducing on-target platelet toxicity, supporting differentiation in solid tumors and AML. ▪️ REC-4881 (MEK1/2 inhibitor): Strong Phase 2 efficacy signals and a safety profile consistent with the MEK inhibitor class, with FDA engagement initiated to define a potential registrational pathway and an update expected in 2H26. ▪️ Our joint programs with Sanofi continue advancing towards development candidate designation and earlier stage program milestones in the next 12 months, and we expect to continue to translate biological insights from maps delivered to Roche and Genentech into potential target validation milestones over the next 12 months. As CEO and President Najat Khan says, this “represents a growing set of proof points that demonstrate our ability to translate platform insights into clinical programs. This progress reflects the strength of both our internal pipeline and partnerships, with multiple differentiated programs advancing through our end-to-end AI platform.” Our Q1 Earnings report also highlights our disciplined capital execution: reiterating the 2026 guidance of <$390M operational cash burn, and supporting runway into early 2028 without additional financing. 👉 Join our Earnings Call on Wed., May 6 at 8:00 am ET / 6:00 am MT / 1:00 pm BST, here on X and on: ▪️ YouTube: ▪️ LinkedIn: 👉 Analysts, investors, and the public can submit questions here: 👉 Read the full report:
0:25

Today, we announce our Q1 2026 business updates and financial results – demonstrating continued momentum across our internal portfolio and partnered programs, with multiple value-driving milestones on track. 🚀 Key proof points include: ▪️ REC-1245 (RBM39 degrader): Early clinical data demonstrate a well-tolerated safety profile and predictable, dose-dependent PK (n=16); dose escalation ongoing with no dose-limiting toxicities observed to date. ▪️ REC-4539 (LSD1 inhibitor): First patient dosed in Phase 1; platform-derived, selective, brain-penetrant profile with a reversible mechanism and shorter predicted half-life aimed at reducing on-target platelet toxicity, supporting differentiation in solid tumors and AML. ▪️ REC-4881 (MEK1/2 inhibitor): Strong Phase 2 efficacy signals and a safety profile consistent with the MEK inhibitor class, with FDA engagement initiated to define a potential registrational pathway and an update expected in 2H26. ▪️ Our joint programs with Sanofi continue advancing towards development candidate designation and earlier stage program milestones in the next 12 months, and we expect to continue to translate biological insights from maps delivered to Roche and Genentech into potential target validation milestones over the next 12 months. As CEO and President Najat Khan says, this “represents a growing set of proof points that demonstrate our ability to translate platform insights into clinical programs. This progress reflects the strength of both our internal pipeline and partnerships, with multiple differentiated programs advancing through our end-to-end AI platform.” Our Q1 Earnings report also highlights our disciplined capital execution: reiterating the 2026 guidance of <$390M operational cash burn, and supporting runway into early 2028 without additional financing. 👉 Join our Earnings Call on Wed., May 6 at 8:00 am ET / 6:00 am MT / 1:00 pm BST, here on X and on: ▪️ YouTube: ▪️ LinkedIn: 👉 Analysts, investors, and the public can submit questions here: 👉 Read the full report:

Recursion

23,615 görüntüleme • 3 ay önce

Today marks a pivotal moment for Isomorphic Labs. We have secured $2.1 Billion in our second external funding round, led by Thrive Capital. They are joined at the table by Alphabet, GV and new investors MGX, Temasek, CapitalG and the UK Sovereign AI Fund. This milestone accelerates our ability to build the pioneering novel AI models that power our AI drug design engine (IsoDDE) and deploy them at scale: delivering scientific breakthroughs with a precision previously thought impossible, accelerating and expanding our pipeline of therapeutic programs toward the clinic. All with the ultimate goal of delivering life-changing new medicines to patients. Moving forward, we will scale our drug candidate pipelines across multiple therapeutic areas, expand our global footprint, and push the boundaries of frontier AI research to power our drug design engine. Deeply grateful to everyone sharing our vision to solve all disease with AI. Let’s build the future of medicine. Read the full announcement here:
0:36

Today marks a pivotal moment for Isomorphic Labs. We have secured $2.1 Billion in our second external funding round, led by Thrive Capital. They are joined at the table by Alphabet, GV and new investors MGX, Temasek, CapitalG and the UK Sovereign AI Fund. This milestone accelerates our ability to build the pioneering novel AI models that power our AI drug design engine (IsoDDE) and deploy them at scale: delivering scientific breakthroughs with a precision previously thought impossible, accelerating and expanding our pipeline of therapeutic programs toward the clinic. All with the ultimate goal of delivering life-changing new medicines to patients. Moving forward, we will scale our drug candidate pipelines across multiple therapeutic areas, expand our global footprint, and push the boundaries of frontier AI research to power our drug design engine. Deeply grateful to everyone sharing our vision to solve all disease with AI. Let’s build the future of medicine. Read the full announcement here:

Isomorphic Labs

281,210 görüntüleme • 3 ay önce

My doctors gave me a 1 in a million chance to find a cure to my disease. To make things worse, I didn’t have a billion dollars and 10 years to develop a new drug from scratch. My only hope was to find a drug that was already FDA-approved that I could repurpose for my disease. It’s been over 9.5 years that I’ve been in remission and we have been able to identify and advance numerous treatments for diseases they weren’t initially intended for. Now through Every Cure we are utilizing artificial intelligence to maximize the potential of all existing drugs to treat every disease they possibly can. What is a cause that you’re passionate about that people give a 1 in a million chance? #MedTwitter
0:51

My doctors gave me a 1 in a million chance to find a cure to my disease. To make things worse, I didn’t have a billion dollars and 10 years to develop a new drug from scratch. My only hope was to find a drug that was already FDA-approved that I could repurpose for my disease. It’s been over 9.5 years that I’ve been in remission and we have been able to identify and advance numerous treatments for diseases they weren’t initially intended for. Now through Every Cure we are utilizing artificial intelligence to maximize the potential of all existing drugs to treat every disease they possibly can. What is a cause that you’re passionate about that people give a 1 in a million chance? #MedTwitter

David Fajgenbaum, MD

105,087 görüntüleme • 2 yıl önce

It's not uncommon to find 15, or even 50, different organizations dedicated to a single rare disease. This is without a doubt holding the rare disease community back. The reality is that compared to more common diseases, rare diseases already face significant hurdles in accessing resources. This scarcity is amplified by the fragmentation of groups. Each organization, operating in isolation, struggles to gather sufficient patient data and biospecimens, which are crucial for advancing research and treatment options. Imagine the potential if these groups could unite their efforts. By combining resources, sharing data, and collaborating on research, we could accelerate progress in ways that are currently out of reach. How can we foster greater unity in the rare disease community? What steps can we take to ensure that every organization, family, and patient is part of a larger, more effective network? #MedTwitter
0:33

It's not uncommon to find 15, or even 50, different organizations dedicated to a single rare disease. This is without a doubt holding the rare disease community back. The reality is that compared to more common diseases, rare diseases already face significant hurdles in accessing resources. This scarcity is amplified by the fragmentation of groups. Each organization, operating in isolation, struggles to gather sufficient patient data and biospecimens, which are crucial for advancing research and treatment options. Imagine the potential if these groups could unite their efforts. By combining resources, sharing data, and collaborating on research, we could accelerate progress in ways that are currently out of reach. How can we foster greater unity in the rare disease community? What steps can we take to ensure that every organization, family, and patient is part of a larger, more effective network? #MedTwitter

David Fajgenbaum, MD

27,305 görüntüleme • 2 yıl önce

Thanks Ashish Ashish M. Kamat, MD, MBBS. Your book entitled, "Bladder Cancer: A Practical Guide" says it all. Together we face patients on a day-to-day level in which we have to make decisions in the best interest of the patient with nothing else considered. I was so grateful for you to have shared with me your views on whether CIS and papillary from a clinical perspective was the same disease and also how you treat patients who have failed all BCG and have papillary disease and face losing their bladder to a life-changing operation of cystectomy. I was blown away at this year's #AUA2026 when a researcher presented a slide showing that the morbidity and mortality of a cystectomy exceeds even that of a Whipple in which the pancreas, gallbladder portion of the stomach and spleen are all removed. That blew my mind especially since there is an option to save the bladder. I am posting the segment of our long conversation relating to your views of whether CIS and high grade papillary are treated clinically as the same disease. I was glad to hear the next day at the FDA workshop that your fellow expert colleagues completely agreed with this sentiment that you expressed in our conversation.
0:27

Thanks Ashish Ashish M. Kamat, MD, MBBS. Your book entitled, "Bladder Cancer: A Practical Guide" says it all. Together we face patients on a day-to-day level in which we have to make decisions in the best interest of the patient with nothing else considered. I was so grateful for you to have shared with me your views on whether CIS and papillary from a clinical perspective was the same disease and also how you treat patients who have failed all BCG and have papillary disease and face losing their bladder to a life-changing operation of cystectomy. I was blown away at this year's #AUA2026 when a researcher presented a slide showing that the morbidity and mortality of a cystectomy exceeds even that of a Whipple in which the pancreas, gallbladder portion of the stomach and spleen are all removed. That blew my mind especially since there is an option to save the bladder. I am posting the segment of our long conversation relating to your views of whether CIS and high grade papillary are treated clinically as the same disease. I was glad to hear the next day at the FDA workshop that your fellow expert colleagues completely agreed with this sentiment that you expressed in our conversation.

Dr. Pat Soon-Shiong

42,739 görüntüleme • 3 ay önce